Exploratory Advanced Radiotherapies for Ameloblastoma and Ameloblastic Carcinoma-A Concise Review.

IF 2.9 3区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral diseases Pub Date : 2025-06-10 DOI:10.1111/odi.15403

Heba Turkstani, Afrah Alfaifi, Sunday O Akintoye

{"title":"Exploratory Advanced Radiotherapies for Ameloblastoma and Ameloblastic Carcinoma-A Concise Review.","authors":"Heba Turkstani, Afrah Alfaifi, Sunday O Akintoye","doi":"10.1111/odi.15403","DOIUrl":null,"url":null,"abstract":"Objective: Ameloblastoma is an aggressively growing odontogenic tumor with substantial management challenges and a high recurrence rate. Surgical resection is the treatment of choice for ameloblastoma, but adjuvant therapies like radiation have been explored in cases where surgery is not clinically advisable and the tumor is inoperable. This short review assessed ameloblastoma case reports for outcomes of advanced radiation therapy modalities.Methods: PubMed, Google Scholar, Embase, Web of Science, and Scopus databases were queried for outcomes of ameloblastoma treated with helical tomotherapy, gamma knife radiosurgery, proton beam therapy, and carbon ion therapy. Patient outcomes were assessed based on tumor response, radiation side effects, and tumor recurrence.Results: Seven of nine (78%) cases showed tumor regression or complete response, with no disease progression during follow-up that ranged from 3 months to 5 years. The remaining two had partial regression or stable disease. Treatment side effects were generally mild, with 6 cases reporting grade 1-3 dermatitis, mucositis, or xerostomia. Two cases experienced severe toxicity, including grade 3 mucositis and radiation retinopathy.Conclusion: Advanced radiation techniques offer a promising alternative or adjuvant therapy for ameloblastoma in cases where surgery is contraindicated. However, more studies are needed to validate these findings.","PeriodicalId":19615,"journal":{"name":"Oral diseases","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12266360/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/odi.15403","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Ameloblastoma is an aggressively growing odontogenic tumor with substantial management challenges and a high recurrence rate. Surgical resection is the treatment of choice for ameloblastoma, but adjuvant therapies like radiation have been explored in cases where surgery is not clinically advisable and the tumor is inoperable. This short review assessed ameloblastoma case reports for outcomes of advanced radiation therapy modalities.

Methods: PubMed, Google Scholar, Embase, Web of Science, and Scopus databases were queried for outcomes of ameloblastoma treated with helical tomotherapy, gamma knife radiosurgery, proton beam therapy, and carbon ion therapy. Patient outcomes were assessed based on tumor response, radiation side effects, and tumor recurrence.

Results: Seven of nine (78%) cases showed tumor regression or complete response, with no disease progression during follow-up that ranged from 3 months to 5 years. The remaining two had partial regression or stable disease. Treatment side effects were generally mild, with 6 cases reporting grade 1-3 dermatitis, mucositis, or xerostomia. Two cases experienced severe toxicity, including grade 3 mucositis and radiation retinopathy.

Conclusion: Advanced radiation techniques offer a promising alternative or adjuvant therapy for ameloblastoma in cases where surgery is contraindicated. However, more studies are needed to validate these findings.

查看原文本刊更多论文

成釉细胞瘤和成釉细胞癌的先进放射治疗研究综述。

目的：成釉细胞瘤是一种侵袭性生长的牙源性肿瘤，治疗难度大，复发率高。手术切除是成釉细胞瘤的首选治疗方法，但在临床上不建议手术和肿瘤不能手术的情况下，已经探索了放射等辅助治疗。这篇简短的综述评估了成釉细胞瘤病例报告的先进放射治疗方式的结果。方法：检索PubMed、谷歌Scholar、Embase、Web of Science和Scopus数据库，查询螺旋断层治疗、伽玛刀放射治疗、质子束治疗和碳离子治疗的成釉质细胞瘤的治疗结果。根据肿瘤反应、放射副反应和肿瘤复发来评估患者的预后。结果：9例患者中有7例（78%）肿瘤消退或完全缓解，随访3个月至5年无疾病进展。其余2例部分消退或病情稳定。治疗副作用一般较轻，6例报告1-3级皮炎、粘膜炎或口干。2例出现严重毒性，包括3级黏膜炎和放射性视网膜病变。结论：在手术禁忌的情况下，先进的放射技术为成釉细胞瘤提供了一种有希望的替代或辅助治疗方法。然而，需要更多的研究来验证这些发现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oral diseases 医学-牙科与口腔外科

CiteScore

7.60

自引率

5.30%

发文量

325

审稿时长

4-8 weeks

期刊介绍： Oral Diseases is a multidisciplinary and international journal with a focus on head and neck disorders, edited by leaders in the field, Professor Giovanni Lodi (Editor-in-Chief, Milan, Italy), Professor Stefano Petti (Deputy Editor, Rome, Italy) and Associate Professor Gulshan Sunavala-Dossabhoy (Deputy Editor, Shreveport, LA, USA). The journal is pre-eminent in oral medicine. Oral Diseases specifically strives to link often-isolated areas of dentistry and medicine through broad-based scholarship that includes well-designed and controlled clinical research, analytical epidemiology, and the translation of basic science in pre-clinical studies. The journal typically publishes articles relevant to many related medical specialties including especially dermatology, gastroenterology, hematology, immunology, infectious diseases, neuropsychiatry, oncology and otolaryngology. The essential requirement is that all submitted research is hypothesis-driven, with significant positive and negative results both welcomed. Equal publication emphasis is placed on etiology, pathogenesis, diagnosis, prevention and treatment.